2027 Pharma Quality Outlook: From Inspection Readiness to Continuous Risk Control

The regulatory, supplier, data-integrity, and AI priorities that should shape your quality agenda in the year ahead

Pharmaceutical quality organizations enter 2027 facing a familiar mandate with much higher expectations: remain inspection-ready, protect product quality, manage an increasingly complex supplier network, and make faster decisions from growing volumes of quality data.

Yet many companies still manage deviations, CAPAs, supplier issues, audit findings, laboratory events, risks, and regulatory evidence in disconnected processes. The result is delayed signals, recurring problems, investigation backlogs, and intense preparation whenever an inspection approaches.

This webinar will examine the quality priorities that should shape the 2027 Pharma agenda and what it takes to move from record closure to continuous risk control. We will explore how connected quality data, risk-based decision-making, supplier intelligence, and responsibly applied AI can help organizations identify emerging issues earlier, strengthen investigation effectiveness, and maintain a sustained state of inspection readiness.

Attendees will leave with a practical framework for assessing where their quality systems remain reactive, where risk visibility is fragmented, and which capabilities deserve priority in their 2027 quality transformation plans.

Attendees will learn:

• Which quality and compliance pressures should influence Pharma quality plans for 2027
• Why closing deviations and CAPAs is not the same as controlling recurrence and risk
• How to connect signals from suppliers, laboratories, manufacturing, audits, complaints, and change control
• How AI can support investigations, trend detection, prioritization, and decision-making without replacing accountable quality oversight
• How to establish practical leading indicators for continuous inspection readiness